Document Detail

Focal macular electroretinograms after photodynamic therapy combined with intravitreal bevacizumab.
MedLine Citation:
PMID:  21038080     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Retinal function is transiently depressed after photodynamic therapy (PDT) alone. One of the reasons for this functional impairment is a reduction of choroidal circulation caused by the PDT. The purpose of this study was to determine whether PDT combined with intravitreal bevacizumab (PDT+IVB) can reduce or prevent the transient impaired macular function. In addition, we examined whether a significant correlation existed between the changes in the focal macular electroretinograms (FMERGs), optical coherence tomography (OCT)-determined morphology, and changes in choroidal circulation.
METHODS: Thirty-eight eyes that were treated by full fluence PDT+IVB were studied. FMERGs, OCT, and indocyanine green angiography (ICGA) were performed before and after the PDT. The intensity of the diffuse fluorescence within the PDT site was measured by densitometry (I/N ratio).
RESULTS: The macula was significantly thinner 1 week after PDT+IVB (P < 0.01). The mean a- and b-wave amplitudes of the FMERGs were not significantly decreased 1 week after PDT+IVB. The mean b-wave amplitudes 3 months after PDT+IVB were significantly increased (P < 0.01). The I/N ratio of ICGA 3 months after PDT+IVB was 0.88 ± 0.1. The correlation between the FMERGs and I/N ratio was not significant.
CONCLUSION: The use of IVB with PDT mitigates the reduction of the FMERGs and reduces the macular thickness soon after PDT, regardless of the degree of impairment of choroidal circulation caused by PDT. Finally, the macular retinal function 3 months after PDT+IVB were better than that before the treatment.
Kohei Ishikawa; Hiroaki Nishihara; Shinsuke Ozawa; Chang-Hua Piao; Yasuki Ito; Mineo Kondo; Hiroko Terasaki
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-10-31
Journal Detail:
Title:  Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv für klinische und experimentelle Ophthalmologie     Volume:  249     ISSN:  1435-702X     ISO Abbreviation:  Graefes Arch. Clin. Exp. Ophthalmol.     Publication Date:  2011 Feb 
Date Detail:
Created Date:  2011-02-21     Completed Date:  2011-05-20     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  8205248     Medline TA:  Graefes Arch Clin Exp Ophthalmol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  273-80     Citation Subset:  IM    
Department of Ophthalmology, Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya, 466-8550, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiogenesis Inhibitors / therapeutic use*
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Choroid / blood supply
Choroidal Neovascularization / drug therapy*,  physiopathology
Coloring Agents / diagnostic use
Combined Modality Therapy
Fluorescein Angiography
Indocyanine Green / diagnostic use
Intravitreal Injections
Macular Degeneration / drug therapy*,  physiopathology
Regional Blood Flow / physiology
Retina / physiology
Retrospective Studies
Tomography, Optical Coherence
Vascular Endothelial Growth Factor A / antagonists & inhibitors
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Coloring Agents; 0/VEGFA protein, human; 0/Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V/bevacizumab; 3599-32-4/Indocyanine Green

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Vagus nerve stimulation: effectiveness and tolerability in patients with epileptic encephalopathies.
Next Document:  Mid-term results of PLIF/TLIF in trauma.